The dose enhancement effect of various paramagnetic nanoshells irradiated with various brachytherapy sources was calculated.
Introduction
Brachytherapy is a commonly used cancer treatment method, with the main goal of maximizing tumor dose and minimizing the dose in surrounding normal tissues. The presence of a high-atomic-number material in tumor cells results in a dose enhancement effect, and thus application of such materials in radiotherapy has been suggested [1] [2] [3] [4] [5] [6] [7] . Nanoparticles (NPs) with high atomic numbers, such as gold, are candidates for such applications. The increase in the photoelectric effect relative to the tissue medium is proportional the cube of the atomic number of the particles. Some other types of NP such as gadolinium (Gd), iron oxide (in the form of Fe 2 O 3 or Fe 3 O 4 ), manganese (Mn), and dysprosium (Dy) can be used as contrast agents in magnetic resonance imaging (MRI). These NPs are paramagnetic and to avoid their toxicity, they are used in a bounded form with diethylenetriaminepentaacetic acid (DTPA) [8] . The NP form of these agents in combination with DTPA has a different toxicity profile than those of the NPs or DTPA alone. Nanoshells (NShs) are a novel group of spherical NPs consisting of a core and a metallic shell. In this study, the shell and the core complex are referred to as the shell/core. NShs are attractive due to their potential in cancer diagnosis and treatment. The most common NShs used in medicine are gold/silica and their application for cancer treatment and imaging has been explored [9] [10] [11] . Gold/silica NShs have specific optical properties, which are beneficial in cancer treatment when irradiated by a laser beam. The optical properties of these NShs strongly depend on the ratio of the core size to the shell thickness [10, 12, 13] . In a study by Gheorghe et al. , it was observed that the optical responses of Au: Ag alloy/ Gd:Fe 3 O 4 NShs depend on the shell thickness [14] . The radiative properties of gold NShs make them useful for molecular cancer imaging and therapeutic applications [10] . According to the results of Loo et al., gold/silica NShs can enhance the contrast of optical coherence tomography and can be used in the near-infrared thermal therapy of cancers [10] . Recently, Au 3 Cu 1 NShs have been fabricated which enhance signal contrast in both T 1 -and T 2 -weighted imaging. However, a dose-dependent toxic effect of the Au 3 Cu 1 NShs was observed (83% of experimental mice were alive at a dose of 20 mg/kg) [15] .
Gold and silver NPs have been proven to be almost biocompatible when they are used in low concentrations [16, 17] and their dose enhancement effects in brachytherapy and teletherapy have been investigated [1] [2] [3] . Roeske et al. analyzed the dose enhancement by materials with atomic numbers in the range of 25 to 90 subjected to a number of external beam X-ray and brachytherapy sources [18] . The results showed a DEF of less than 1.05 for all materials with a concentration of 5 mg/ml for 60 Co, 192 Ir, 198 Au, and 137 Cs sources and 6, 18, and 25 MV X-rays. However, the DEF values for 50-, 80-, 100-, and 140-kVp X-ray sources, and 103 Pd and 125 I sources were higher.
The DEF increased for all sources with increasing atomic number (Z) in the Z range of 25 to 35. For Z ranging from 40 to 60, the DEF reaches a plateau or slightly decreases as energy increases. For materials with Z higher than 70, the DEF increases. Based on the results, high-atomic-number NPs in combination with low-energy sources significantly enhance the absorbed dose. Ngwa et al. used theoretical microdosimetry at a subcellular level to estimate the dose enhancement of tumor endothelial cell nuclei due to the presence of gold NPs in tumor endothelium in brachytherapy [19] . The tumor vascular endothelial cell was modeled as a 2 μm × 10 μm × 10 μm slab. The endothelial cell contained a nucleus with a 5-μm diameter and a 0.5-1 μm thickness. 125 I, 103 Pd, 169 Yb, and 50 kVp X-ray brachytherapy sources were investigated. Depending on the gold NP concentration and type of photon source used, the nucleus dose enhancement factor ranged from 3.2 to 73 and from 3.3 to 79.2 for nucleus sizes of 10% and 5%, respectively. The results suggest that a significant dose increase to the nucleus of endothelial cells can be obtained by the combination of gold NPs and brachytherapy sources. Furthermore, it was concluded that this dose enhancement results in increased tumor cell death.
Cho performed a Monte Carlo study to calculate the dose enhancement for several phantoms representing radiation treatments with 140-kVp X-rays, 192 Ir gamma rays, and 4-and 6-MV photon beams [20] . Three levels of gold concentration were considered within the tumor. For a 7 mg Au/g tumor (~7 mg Au/ml tumor) concentration, the dose enhancement in the tumor volume for 140-kVp X-rays was at least a factor of 2. The tumor dose enhancement for 4-and 6-MV photons ranged from about 1% to 7%, depending on the concentration of gold and energies of photons. The results have also shown that loading gold into surrounding normal tissue at the 2 mg Au/g level (~2 mg Au/ml) resulted in an increase in the dose enhancement in normal tissue while the dose enhancement in the tumor was unchanged. 
Materials and methods

Brachytherapy sources
Dosimetric source parameters
Based on the updated Task Group No. 43 (TG-43U1) formalism [26] , the dose rate constant and radial dose function of the four sources were calculated. The dose rate constant (cGyh -1 U -1 ), Λ, is defined as the ratio of the dose rate at the reference point in water,
, and the air kerma strength,
The radial dose function (g(r)) is calculated using:
refer to dose rates at (r, θ 0 ) and (r 0 , θ 0 ), respectively (r 0 = 1 cm and θ 0 = π/2). G(r, θ) refers to the geometry function, which is defined for a line source as:
where β is the angle between the tips of the linear source and the calculation point, L is the active length of the linear source, r is the radial distance in the transverse plane, and θ is the polar angle of the calculation point relative to the longitudinal axis of the source. These parameters were compared with the corresponding previously published data for the four source models [22] [23] [24] [25] to validate the simulations. For air kerma strength calculation, air toruses with thicknesses of 0.1 cm at radial distances ranging from 1 to 50 cm were defined around each line source. The average air kerma rate in the toruses in the almost flat region of (r 2 × kerma rate) versus r plot was used for the air kerma strength calculation. The F6 tally was used to obtain air kerma rates in the toruses, which has been previously done [1, 3] . To calculate the dose rate constant, the *F8 tally was obtained at a radial distance of 1 cm in a water phantom. The value of the dose rate constant was determined as the ratio of the dose rate at a distance of 1 cm in water to the air kerma strength. The radial dose function was calculated based on the approach of the TG-43U1 protocol [26] in a spherical water phantom with a radius of 50 cm. Line-source approximation was used for the calculation of the radial dose function for the 125 I, 103 Pd, 169 Yb, and 192 Ir brachytherapy sources. The *F8 tally was obtained in the toruses of 0.1-cm thickness at radial distances of 0.5 to 7 cm from the source. The energy cut-off for photons and electrons was set to 5 keV and 1.5 × 10 8 photon histories were followed. In this step, the corresponding type A statistical uncertainties in the Monte Carlo calculations were less than 2.9%. This type of uncertainty specifies the uncertainty related to the statistical errors in MC code calculations [29] .
Dose enhancement calculations
After verification of the simulated sources by comparison of their dosimetric parameters with the published data, the source simulation files were used to calculate the DEFs in the presence of NShs in tumor tissue. For this purpose, a spherical phantom with a radius of 15 cm composed of soft tissue was simulated. The composition of soft tissue was assumed to be that in report No. 44 of the International Commission on Radiation Units and Measurements (ICRU): 76.2% oxygen, 11.1% carbon, 10.1% hydrogen, and 2.6% nitrogen [30] . Four types of NShs were simulated in this study: Au/Gd, Au/Fe 2 O 3 , Ag/Dy, and Ag/Mn, where the first element indicates the constituent of the shell and the second one indicates that of the core. All of these NShs were assumed to have a core radius of 50 nm and a shell thickness of 10 nm (a total diameter of 120 nm). These types of NShs were designed to ensure biocompatibility of their shells (i.e., Au and Ag) [16, 17] . The concentration levels of gold and silver NShs in the tumor were 10, 20, and 30 mg/ml tumor, which are approximately the same order as the values in the studies by Cho et al. and Cho (7, 18 , and 30 mg Au/g ~7, 18, and 30 mg Au/ml) [2, 20] [31] . The tumor volume was modeled as a 1 cm × 1 cm × 1 cm cube with the center positioned at 1 cm from the center of the source, which was located at the center of the phantom. The tumor composition was assumed to be the same as that of the soft tissue phantom while the compositions of NShs with the aforementioned concentrations were added to the tumor. Changes in density and composition of the tumor due to the addition of NShs were considered as well. To show the dose enhancement effect of NShs, the DEF was calculated for the above mentioned NShs for 125 the total number of electrons for the NSh shell and core, respectively, and Z s and Z c are the atomic numbers of the constituent elements of the shell and core, respectively. The energy cut-off for photon and electron transport was set as 10 keV and the photon histories followed were set to 1. Pd source. For the voxels closer to the source, the statistical uncertainties were less than this level. 
Results
Dose rate constant and radial dose function
The from the source and the percentage differences between two studies are presented in Table 4 . The comparisons of the data in the two studies are based on the percentage differences of our results and the values reported by the other studies for the same source models. The negative percentage differences in these tables indicate that the values reported here were less than the compared values. The blank cells in Table 4 are for points without any data in the reference report with which our data was compared.
Dose enhancement in presence of NShs
The average values of DEFs in the tumor for Au/Gd, Au/Fe 2 O 3 , Ag/Dy, and Ag/Mn NShs with concentrations of 10, 20, and 30 mg/ml tumor for 125 
Discussion
This study was performed to evaluate the dose enhancement effect of various paramagnetic NShs in brachytherapy. It is indicated in Table 3 that the maximum discrepancy for the dose rate constant (cGyh -1 U -1 ) from our study and the published value is -6.28% for the 125 I source. The maximum discrepancy for the radial dose function, shown in Table 4 , is 8.50% for the 103 Pd source at a radial distance of 5 cm. The differences are much lower than 8.50% for other sources and radial distances. Our calculated values of dose rate constant and radial dose function for the four sources are in good agreement with previously published data. The anisotropy function difference of 2-5% was interpreted as being in excellent agreement with the data from the the TG-43 updated report [33] . To verify low-energy (  125 I and   103 Pd) and highenergy ( 169 Yb and 192 Ir) brachytherapy source simulations, the recommendations of the AAPM Task Group No. 43 report and an updated report for high-energy sources were adopted [34] . The latter report includes recommendations on the selection of phantom size, energy cut-off, voxel size, etc. for the simulation of high-energy brachytherapy sources as they have an effect on the acuracy of source simulations. DEF values obtained in the presence of Au/Gd, Au/Fe 2 O 3 , Ag/Dy, and Ag/Mn NShs in the tumor (Table 5) indicate that these NShs can be used as dose enhancement agents with the considered photon-emitting brachytherapy sources. The combination of NShs with brachytherapy could potentially reduce the delivery time or the number of treatment fractions required for high-dose-rate brachytherapy, or the implanted radioactivity for low-dose-rate brachytherapy. The dose enhancement effect calculated herein was the ratio of the dose in a voxel in the presence of NShs to that without them. Since the NShs were defined as nanospheres, the deposited energy in the presence of the nanospheres is the sum of the energy deposition inside them and that in soft tissue. From the biological point of view, the dose component inside the nanospheres may not be sufficient to damage cells. We did not separate these two dose components. However, in a study by Ghorbani et al. [3] , dose enhancement was evaluated for four brachytherapy sources with 50-, 100-, and 200-nm gold NPs by two methods: a precise definition of NPs using the lattice option and a simple model based on the atomic definition of a gold and soft tissue mixture. Based on their results, the simple model overestimated the dose enhancement and the differences between these two methods were related to the precision of the methods. However, when one considers the two dose components including the dose inside and outside the nanospheres, the difference can be related partially to the shielding effect of NPs, which is ignored in the simple model. Leung et al. [35] calculated the ratio of energy deposition outside a gold NP to the total energy deposition (selfabsorbtion plus absorption outside the gold NP). Over 65% and 90% of the total energy deposition was outside the gold NP for 50 and 250 kVp, respectively. These values indicate that the energy deposition is mainly due to the dose enhancement effect rather than the shielding effect.
It is indicated in Table 5 that lower-energy sources, such  as  125 I,   103 Pd, and 169 Yb, produce a significant dose enhancement effect in the presence of NShs. However, the higher-energy 192 Ir source does not show dose enhancement for lower-atomic-number NShs when one considers the related uncertainties in dose enhancement calculations. The probability of photoelectric absorption depends inversely on the third power of photon energy (1/E 3 ) [36] and for low-energy photons this phenomenon is the most probable interaction. Thus, higher DEFs for low-energy photon-emitting sources are reasonable. It is shown in Pd compare to that for 125 I.
As indicated in Table 6 , among the four NSh types, Au/Gd with a Z eff of 74.21 has the highest DEF with all the concentrations and sources, while Ag/Mn with a Z eff of 39.03 has the lowest DEF. This is due to the photoelectric effect, which has higher probability of occurrence with higheratomic-number materials. As shown in sources have more uniform dose distributions in the tumor volume in the presence of NShs which seems to be of clinical benefit. However, the physical properties of the interaction of photons with these NShs are not completely known; similar to NPs, they may be dependent on the type and size of the NShs [38] . For the 125 I source, the mean value of DEF for 30 mg/ml tumor and Ag/Mn NShs is 2.78 ± 0.01 with a 1-keV energy cut-off and 2.77 ± 0.02 with a 10-keV energy cut off. The data shown here indicate that similar dose enhancements are obtained with 1-and 10-keV energy cut-offs. This is because the tally was taken in 2 × 2 × 2 mm 3 cells, and the short-range secondary particles deposit their energy locally, resulting in an unchanged DEF. In other words, a 10-keV energy cut-off does not mean that the particles are eliminated at energies at or below 10 keV, but rather that the photon energy is deposited at the point in which the particle's energy reaches 10 keV. Calculated DEFs for the evaluated NShs are comparable with DEFs of NPs reported in other published studies. For example, based on the results of a study by Ghorbani et al., the DEF for gold NPs with a diameter of 100 nm and a concentration of 30 mg/ml tumor for 125 I source is 3.62 [3] .
This value is comparable with the DEF of Au/Gd NShs in this study with a diameter of 120 nm and the same concentration and source (3.25) ( Table 5 ). When one considers these values, the DEF of Au/Gd NShs is lower than that of gold NPs. The difference may be related to the differences in Z eff and unequal diameters of gold and Au/Gd NPs in these two studies.
A common method for brachytherapy source verification is to use the spectrum reported in other published articles on that source. Several published studies on TG-43 dosimetric parameters have based their source spectra on previously published articles. There are also national laboratories [39] which report updated spectra for radionuclides. There may be differences between the spectra in the published articles and these laboratories for a single radionuclide. Using the updated spectrum data from national laboratories may have advantages. The dimension of NShs in this study (120 nm) was selected according to the study by Park et al. [40] . In the study by Ghorbani et al. [3] , it was reported that dose enhancement increases with increasing size of gold NPs. The size of 120 nm in the present study is one possible realization. One of our limitations is the zero concentration of the NShs in normal tissue. Certainly, the results in real situations differ from simulated ones because the injected NShs will be absorbed in some extent in normal tissues. In the study by Hainfeld et al. [31] tumor-to-normal-tissue gold concentration ratios remained at ∼8:1 during the first minutes of radiotherapy. Cho [20] assumed a concentration level of 2 mg Au/g in normal tissue, which resulted in up to a 31% increase in the normal tissue dose. Our results are only based on the simulations of NShs and brachytherapy sources. Other aspects such as the in vitro and in vivo evaluation of the cytotoxicity of NShs, applicable concentrations, size effect of NShs, etc. can be as the subject of further evaluations in this field. Clinical application of the proposed NShs for dose enhancement in brachytherapy will require preclinical studies on various aspects of the use of a newly proposed treatment method. In this study, a sphere phantom with a 15-cm radius was simulated by MCNPX code. The results obtained for a cubic tumor cannot simply be extended for tumors with different compositions and geometrical shapes. In this study, the center of the tumor was located 1 cm from the source, which was adopted according to previous studies [1] [2] [3] . The results for this case may differ from those for other relative tumor-source positions. In the present study, NShs with homogeneous distributions were defined throughout the tumor while in a real case this is not an easily achievable situation. The concentration of nanospheres may be inhomogeneous in a tumor volume and this will result in nonuniform dose enhancement values inside the tumor. Furthermore, when NShs are injected into the body, they will be absorbed by surrounding normal tissues to some extent. This absorption will increase the normal tissue dose as well. Studies that take the above-mentioned considerations into account should be conducted.
The NShs considered in this study were designed due to their usefulness in both radiotherapy and MRI. They consist of a biocompatible high-atomic-number shell (Au, Ag) and a paramagnetic core (Gd, Fe 2 O 3 , Dy, or Mn), which make them beneficial in both radiotherapy and visualizing cancers. The biocompatible shells of the proposed NShs are expected to reduce toxicity relative to the cores alone without shells. However, the toxicity effect of the proposed NShs depends on the level of their absorption by normal tissues and their concentrations inside the normal tissues. The term "biocompatible shell" thus does not mean that these NShs are nontoxic.
Conclusion
The dose enhancement effect of various paramagnetic NShs irradiated with various brachytherapy sources was calculated. The calculated dosimetric parameters of four sources were in good agreement with previously published data. The DEFs observed for various NShs in this study are in the range of 1.01-3.25 (Table 3) . Based on these results, it can be concluded that NShs can enhance brachytherapy tumor doses with various sources. Our results show that the best dose enhancements are obtained for higher concentrations of NShs. Furthermore, according to the calculated DEFs, a higher dose enhancement effect occurs with lower-energy radionuclides such as 125 I. In comparison with other sources, the application of an 125 I source will result in the maximum delivered dose to the tumor in the presence of NShs inside the tumor. The proposed paramagnetic NShs could be applied in brachytherapy for dose enhancement and simultaneously can be used as a contrast agent to make tumors visible in MRI. However, clinical application of NShs in brachytherapy needs more preclinical studies in various aspects as a newly proposed treatment method.
